@article{oai:repo.qst.go.jp:00047118,
 author = {Sugyo, Aya and B, Tsuji Atsushi and Sudo, Hitomi and Nagatsu, Kotaro and Koizumi, Mitsuru and Ukai, Yoshinori and Kurosawa, Gene and Zhang, Ming-Rong and Kurosawa, Yoshikazu and Saga, Tsuneo and 須尭 綾 and 辻 厚至 and 須藤 仁美 and 永津 弘太郎 and 小泉 満 and 張 明栄 and 佐賀 恒夫},
 issue = {3},
 journal = {Nuclear medicine communications},
 month = {Mar},
 note = {Pancreatic cancer is aggressive and its prognosis remains poor; thus, effective therapy is urgently needed. Transferrin receptor (TfR) is highly expressed in pancreatic cancer and is considered to be a good candidate for molecular-targeted therapy. We radiolabeled and evaluated fully human anti-TfR monoclonal antibodies as a new PET probe for evaluating the biodistribution of the anti-TfR antibody in pancreatic cancer.},
 pages = {286--294},
 title = {Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.},
 volume = {36},
 year = {2015}
}